Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
47
LNTH Quote, Financials, Valuation and Earnings
Last price:
$67.85
Seasonality move
:
21.75%
Day range:
$68.68 - $70.33
52-week range:
$47.25 - $111.29
Dividend yield:
0%
P/E ratio:
29.13x
P/S ratio:
3.17x
P/B ratio:
4.11x
Volume:
1.3M
Avg. volume:
1.1M
1-year change:
-28.43%
Market cap:
$4.6B
Revenue:
$1.5B
EPS (TTM):
$2.38
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
LNTH
Lantheus Holdings, Inc.
|
$368M | $1.16 | -5.92% | -29.39% | $83.14 |
|
ALGN
Align Technology, Inc.
|
$1B | $2.96 | 3.68% | 112.55% | $180.47 |
|
COO
The Cooper Cos., Inc.
|
$1.1B | $1.11 | 6.12% | 98.42% | $90.50 |
|
CYTK
Cytokinetics, Inc.
|
$7.6M | -$1.35 | -55.38% | -6.45% | $86.56 |
|
IART
Integra LifeSciences Holdings Corp.
|
$429.6M | $0.80 | -2.94% | 217.65% | $15.50 |
|
TNDM
Tandem Diabetes Care, Inc.
|
$276.9M | -$0.09 | -2.02% | -4.07% | $24.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
LNTH
Lantheus Holdings, Inc.
|
$69.37 | $83.14 | $4.6B | 29.13x | $0.00 | 0% | 3.17x |
|
ALGN
Align Technology, Inc.
|
$166.81 | $180.47 | $12B | 32.32x | $0.00 | 0% | 3.07x |
|
COO
The Cooper Cos., Inc.
|
$83.90 | $90.50 | $16.4B | 44.77x | $0.01 | 0% | 4.10x |
|
CYTK
Cytokinetics, Inc.
|
$65.42 | $86.56 | $8B | -- | $0.00 | 0% | 89.27x |
|
IART
Integra LifeSciences Holdings Corp.
|
$13.15 | $15.50 | $1B | 70.14x | $0.00 | 0% | 0.61x |
|
TNDM
Tandem Diabetes Care, Inc.
|
$22.71 | $24.81 | $1.5B | -- | $0.00 | 0% | 1.51x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
LNTH
Lantheus Holdings, Inc.
|
35.63% | -1.750 | 18.22% | 2.30x |
|
ALGN
Align Technology, Inc.
|
2.97% | 1.077 | 1.34% | 1.08x |
|
COO
The Cooper Cos., Inc.
|
25.25% | -0.042 | 20.32% | 0.89x |
|
CYTK
Cytokinetics, Inc.
|
177.12% | 1.240 | 17.83% | 6.81x |
|
IART
Integra LifeSciences Holdings Corp.
|
65.91% | 0.037 | 179.84% | 1.47x |
|
TNDM
Tandem Diabetes Care, Inc.
|
77.16% | 1.942 | 54.61% | 1.79x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
LNTH
Lantheus Holdings, Inc.
|
$222.4M | $43.6M | 9.52% | 14.66% | 11.36% | $94.7M |
|
ALGN
Align Technology, Inc.
|
$667.1M | $156.1M | 9.43% | 9.72% | 15.67% | $169M |
|
COO
The Cooper Cos., Inc.
|
$601M | $140.4M | 3.45% | 4.56% | 13.18% | $149.9M |
|
CYTK
Cytokinetics, Inc.
|
-$743K | -$166.8M | -120.55% | -- | -8613.38% | -$116.9M |
|
IART
Integra LifeSciences Holdings Corp.
|
$226.1M | $25.9M | -14.85% | -37.15% | 6.43% | $25.8M |
|
TNDM
Tandem Diabetes Care, Inc.
|
$134.3M | -$20.1M | -31.16% | -110.24% | -8.05% | $4.2M |
Lantheus Holdings, Inc. vs. Competitors
-
Which has Higher Returns LNTH or ALGN?
Align Technology, Inc. has a net margin of 7.23% compared to Lantheus Holdings, Inc.'s net margin of 5.7%. Lantheus Holdings, Inc.'s return on equity of 14.66% beat Align Technology, Inc.'s return on equity of 9.72%.
Company Gross Margin Earnings Per Share Invested Capital LNTHLantheus Holdings, Inc.57.91% $0.41 $1.7B ALGNAlign Technology, Inc.67% $0.78 $4.1B -
What do Analysts Say About LNTH or ALGN?
Lantheus Holdings, Inc. has a consensus price target of $83.14, signalling upside risk potential of 19.85%. On the other hand Align Technology, Inc. has an analysts' consensus of $180.47 which suggests that it could grow by 8.19%. Given that Lantheus Holdings, Inc. has higher upside potential than Align Technology, Inc., analysts believe Lantheus Holdings, Inc. is more attractive than Align Technology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LNTHLantheus Holdings, Inc.9 2 0 ALGNAlign Technology, Inc.7 8 0 -
Is LNTH or ALGN More Risky?
Lantheus Holdings, Inc. has a beta of -0.109, which suggesting that the stock is 110.898% less volatile than S&P 500. In comparison Align Technology, Inc. has a beta of 1.833, suggesting its more volatile than the S&P 500 by 83.34%.
-
Which is a Better Dividend Stock LNTH or ALGN?
Lantheus Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Align Technology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lantheus Holdings, Inc. pays -- of its earnings as a dividend. Align Technology, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LNTH or ALGN?
Lantheus Holdings, Inc. quarterly revenues are $384M, which are smaller than Align Technology, Inc. quarterly revenues of $995.7M. Lantheus Holdings, Inc.'s net income of $27.8M is lower than Align Technology, Inc.'s net income of $56.8M. Notably, Lantheus Holdings, Inc.'s price-to-earnings ratio is 29.13x while Align Technology, Inc.'s PE ratio is 32.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings, Inc. is 3.17x versus 3.07x for Align Technology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LNTHLantheus Holdings, Inc.3.17x 29.13x $384M $27.8M ALGNAlign Technology, Inc.3.07x 32.32x $995.7M $56.8M
-
Which has Higher Returns LNTH or COO?
The Cooper Cos., Inc. has a net margin of 7.23% compared to Lantheus Holdings, Inc.'s net margin of 7.94%. Lantheus Holdings, Inc.'s return on equity of 14.66% beat The Cooper Cos., Inc.'s return on equity of 4.56%.
Company Gross Margin Earnings Per Share Invested Capital LNTHLantheus Holdings, Inc.57.91% $0.41 $1.7B COOThe Cooper Cos., Inc.56.42% $0.43 $11B -
What do Analysts Say About LNTH or COO?
Lantheus Holdings, Inc. has a consensus price target of $83.14, signalling upside risk potential of 19.85%. On the other hand The Cooper Cos., Inc. has an analysts' consensus of $90.50 which suggests that it could grow by 7.87%. Given that Lantheus Holdings, Inc. has higher upside potential than The Cooper Cos., Inc., analysts believe Lantheus Holdings, Inc. is more attractive than The Cooper Cos., Inc..
Company Buy Ratings Hold Ratings Sell Ratings LNTHLantheus Holdings, Inc.9 2 0 COOThe Cooper Cos., Inc.6 7 1 -
Is LNTH or COO More Risky?
Lantheus Holdings, Inc. has a beta of -0.109, which suggesting that the stock is 110.898% less volatile than S&P 500. In comparison The Cooper Cos., Inc. has a beta of 1.028, suggesting its more volatile than the S&P 500 by 2.836%.
-
Which is a Better Dividend Stock LNTH or COO?
Lantheus Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Cooper Cos., Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.01 per share. Lantheus Holdings, Inc. pays -- of its earnings as a dividend. The Cooper Cos., Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LNTH or COO?
Lantheus Holdings, Inc. quarterly revenues are $384M, which are smaller than The Cooper Cos., Inc. quarterly revenues of $1.1B. Lantheus Holdings, Inc.'s net income of $27.8M is lower than The Cooper Cos., Inc.'s net income of $84.6M. Notably, Lantheus Holdings, Inc.'s price-to-earnings ratio is 29.13x while The Cooper Cos., Inc.'s PE ratio is 44.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings, Inc. is 3.17x versus 4.10x for The Cooper Cos., Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LNTHLantheus Holdings, Inc.3.17x 29.13x $384M $27.8M COOThe Cooper Cos., Inc.4.10x 44.77x $1.1B $84.6M
-
Which has Higher Returns LNTH or CYTK?
Cytokinetics, Inc. has a net margin of 7.23% compared to Lantheus Holdings, Inc.'s net margin of -15814.98%. Lantheus Holdings, Inc.'s return on equity of 14.66% beat Cytokinetics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LNTHLantheus Holdings, Inc.57.91% $0.41 $1.7B CYTKCytokinetics, Inc.-38.38% -$2.55 $675.7M -
What do Analysts Say About LNTH or CYTK?
Lantheus Holdings, Inc. has a consensus price target of $83.14, signalling upside risk potential of 19.85%. On the other hand Cytokinetics, Inc. has an analysts' consensus of $86.56 which suggests that it could grow by 32.31%. Given that Cytokinetics, Inc. has higher upside potential than Lantheus Holdings, Inc., analysts believe Cytokinetics, Inc. is more attractive than Lantheus Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LNTHLantheus Holdings, Inc.9 2 0 CYTKCytokinetics, Inc.10 3 0 -
Is LNTH or CYTK More Risky?
Lantheus Holdings, Inc. has a beta of -0.109, which suggesting that the stock is 110.898% less volatile than S&P 500. In comparison Cytokinetics, Inc. has a beta of 0.553, suggesting its less volatile than the S&P 500 by 44.718%.
-
Which is a Better Dividend Stock LNTH or CYTK?
Lantheus Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cytokinetics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lantheus Holdings, Inc. pays -- of its earnings as a dividend. Cytokinetics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LNTH or CYTK?
Lantheus Holdings, Inc. quarterly revenues are $384M, which are larger than Cytokinetics, Inc. quarterly revenues of $1.9M. Lantheus Holdings, Inc.'s net income of $27.8M is higher than Cytokinetics, Inc.'s net income of -$306.2M. Notably, Lantheus Holdings, Inc.'s price-to-earnings ratio is 29.13x while Cytokinetics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings, Inc. is 3.17x versus 89.27x for Cytokinetics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LNTHLantheus Holdings, Inc.3.17x 29.13x $384M $27.8M CYTKCytokinetics, Inc.89.27x -- $1.9M -$306.2M
-
Which has Higher Returns LNTH or IART?
Integra LifeSciences Holdings Corp. has a net margin of 7.23% compared to Lantheus Holdings, Inc.'s net margin of -1.34%. Lantheus Holdings, Inc.'s return on equity of 14.66% beat Integra LifeSciences Holdings Corp.'s return on equity of -37.15%.
Company Gross Margin Earnings Per Share Invested Capital LNTHLantheus Holdings, Inc.57.91% $0.41 $1.7B IARTIntegra LifeSciences Holdings Corp.56.24% -$0.07 $3B -
What do Analysts Say About LNTH or IART?
Lantheus Holdings, Inc. has a consensus price target of $83.14, signalling upside risk potential of 19.85%. On the other hand Integra LifeSciences Holdings Corp. has an analysts' consensus of $15.50 which suggests that it could grow by 17.87%. Given that Lantheus Holdings, Inc. has higher upside potential than Integra LifeSciences Holdings Corp., analysts believe Lantheus Holdings, Inc. is more attractive than Integra LifeSciences Holdings Corp..
Company Buy Ratings Hold Ratings Sell Ratings LNTHLantheus Holdings, Inc.9 2 0 IARTIntegra LifeSciences Holdings Corp.2 4 2 -
Is LNTH or IART More Risky?
Lantheus Holdings, Inc. has a beta of -0.109, which suggesting that the stock is 110.898% less volatile than S&P 500. In comparison Integra LifeSciences Holdings Corp. has a beta of 1.025, suggesting its more volatile than the S&P 500 by 2.536%.
-
Which is a Better Dividend Stock LNTH or IART?
Lantheus Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integra LifeSciences Holdings Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lantheus Holdings, Inc. pays -- of its earnings as a dividend. Integra LifeSciences Holdings Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LNTH or IART?
Lantheus Holdings, Inc. quarterly revenues are $384M, which are smaller than Integra LifeSciences Holdings Corp. quarterly revenues of $402.1M. Lantheus Holdings, Inc.'s net income of $27.8M is higher than Integra LifeSciences Holdings Corp.'s net income of -$5.4M. Notably, Lantheus Holdings, Inc.'s price-to-earnings ratio is 29.13x while Integra LifeSciences Holdings Corp.'s PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings, Inc. is 3.17x versus 0.61x for Integra LifeSciences Holdings Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LNTHLantheus Holdings, Inc.3.17x 29.13x $384M $27.8M IARTIntegra LifeSciences Holdings Corp.0.61x 70.14x $402.1M -$5.4M
-
Which has Higher Returns LNTH or TNDM?
Tandem Diabetes Care, Inc. has a net margin of 7.23% compared to Lantheus Holdings, Inc.'s net margin of -8.49%. Lantheus Holdings, Inc.'s return on equity of 14.66% beat Tandem Diabetes Care, Inc.'s return on equity of -110.24%.
Company Gross Margin Earnings Per Share Invested Capital LNTHLantheus Holdings, Inc.57.91% $0.41 $1.7B TNDMTandem Diabetes Care, Inc.53.88% -$0.31 $582.2M -
What do Analysts Say About LNTH or TNDM?
Lantheus Holdings, Inc. has a consensus price target of $83.14, signalling upside risk potential of 19.85%. On the other hand Tandem Diabetes Care, Inc. has an analysts' consensus of $24.81 which suggests that it could grow by 9.25%. Given that Lantheus Holdings, Inc. has higher upside potential than Tandem Diabetes Care, Inc., analysts believe Lantheus Holdings, Inc. is more attractive than Tandem Diabetes Care, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LNTHLantheus Holdings, Inc.9 2 0 TNDMTandem Diabetes Care, Inc.7 13 0 -
Is LNTH or TNDM More Risky?
Lantheus Holdings, Inc. has a beta of -0.109, which suggesting that the stock is 110.898% less volatile than S&P 500. In comparison Tandem Diabetes Care, Inc. has a beta of 1.682, suggesting its more volatile than the S&P 500 by 68.218%.
-
Which is a Better Dividend Stock LNTH or TNDM?
Lantheus Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lantheus Holdings, Inc. pays -- of its earnings as a dividend. Tandem Diabetes Care, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LNTH or TNDM?
Lantheus Holdings, Inc. quarterly revenues are $384M, which are larger than Tandem Diabetes Care, Inc. quarterly revenues of $249.3M. Lantheus Holdings, Inc.'s net income of $27.8M is higher than Tandem Diabetes Care, Inc.'s net income of -$21.2M. Notably, Lantheus Holdings, Inc.'s price-to-earnings ratio is 29.13x while Tandem Diabetes Care, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings, Inc. is 3.17x versus 1.51x for Tandem Diabetes Care, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LNTHLantheus Holdings, Inc.3.17x 29.13x $384M $27.8M TNDMTandem Diabetes Care, Inc.1.51x -- $249.3M -$21.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
70
RGC alert for Jan 8
Regencell Bioscience Holdings Ltd. [RGC] is down 21.5% over the past day.
Buy
64
RVMD alert for Jan 8
Revolution Medicines, Inc. [RVMD] is up 4.61% over the past day.
Sell
38
CRNX alert for Jan 8
Crinetics Pharmaceuticals, Inc. [CRNX] is down 0.23% over the past day.
